Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

by Zacks Equity Research Published on April 10,2017

Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

• LLY Quick QuoteLLYPositive Net Change
• NVO Quick QuoteNVONegative Net Change
• JNJ Quick QuoteJNJPositive Net Change

5 Drug Stocks for Your Portfolio this World Health Day

by Arpita Dutt Published on April 07,2017

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change
• SAGE Quick QuoteSAGEPositive Net Change

AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA

by Zacks Equity Research Published on April 05,2017

AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.

• RHHBY Quick QuoteRHHBYPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

by Zacks Equity Research Published on March 28,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

by Zacks Equity Research Published on March 27,2017

Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

• NVS Quick QuoteNVSPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

by Zacks Equity Research Published on March 23,2017

We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• BMRN Quick QuoteBMRNPositive Net Change
• CPRX Quick QuoteCPRXNegative Net Change

AT&T & Verizon Suspend Marketing Advertisements from YouTube

by Zacks Equity Research Published on March 23,2017

AT&T Inc. (T) and Verizon Communications Inc. (VZ) have decided to suspend their marketing campaign on Google's YouTube site.

• JNJ Quick QuoteJNJPositive Net Change
• GOOGL Quick QuoteGOOGLNegative Net Change

5 Excellent ETFs for Your IRA

by Neena Mishra Published on March 20,2017

Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.

• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLPositive Net Change
• MSFT Quick QuoteMSFTPositive Net Change
• GSLC Quick QuoteGSLCPositive Net Change

Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

by Arpita Dutt Published on March 17,2017

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

• AZN Quick QuoteAZNPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

by Zacks Equity Research Published on March 16,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Large Cap ETF (IVV) Tops $100 billion in AUM

by Sweta Killa Published on March 10,2017

IVV is the second ETF in the space that has managed to garner $100 billion in AUM after SPY.

• JNJ Quick QuoteJNJPositive Net Change
• AAPL Quick QuoteAAPLPositive Net Change
• MSFT Quick QuoteMSFTPositive Net Change

Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

by Zacks Equity Research Published on March 09,2017

Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

• AZN Quick QuoteAZNPositive Net Change
• AGN Quick QuoteAGNPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• ALKS Quick QuoteALKSNegative Net Change

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

by Zacks Equity Research Published on March 07,2017

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

• JNJ Quick QuoteJNJPositive Net Change
• GOOGL Quick QuoteGOOGLNegative Net Change
• SLB Quick QuoteSLBPositive Net Change
• BABA Quick QuoteBABANegative Net Change

J&J Presents Positive Phase III Data on Psoriasis Candidate

by Zacks Equity Research Published on March 06,2017

Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

• JNJ Quick QuoteJNJPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

by Zacks Equity Research Published on March 03,2017

Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

• BMY Quick QuoteBMYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• MRK Quick QuoteMRKPositive Net Change
• ADRO Quick QuoteADROPositive Net Change

Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

by Zacks Equity Research Published on March 02,2017

Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

• JNJ Quick QuoteJNJPositive Net Change
• GERN Quick QuoteGERNNegative Net Change
• CELG Quick QuoteCELGPositive Net Change
• SMMT Quick QuoteSMMTNegative Net Change

by Zacks Equity Research Published on February 28,2017

• JNJ Quick QuoteJNJPositive Net Change
• PFE Quick QuotePFEPositive Net Change
• GSK Quick QuoteGSKPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change

Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research Published on February 27,2017

Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

• JNJ Quick QuoteJNJPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• ACHN Quick QuoteACHNNegative Net Change
• SNSS Quick QuoteSNSSPositive Net Change

Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao

by Swarup Gupta Published on February 24,2017

The Dow notched up a record streak of gains over a holiday shortened week.

• YHOO Quick QuoteYHOONo Net Change
• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change

Johnson & Johnson (JNJ) Up 6% Since Earnings Report: Can It Continue?

by Zacks Equity Research Published on February 24,2017

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• JNJ Quick QuoteJNJPositive Net Change

Geron (GERN) Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research Published on February 17,2017

Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.

• JNJ Quick QuoteJNJPositive Net Change
• GERN Quick QuoteGERNNegative Net Change
• EXAS Quick QuoteEXASPositive Net Change
• PCRX Quick QuotePCRXPositive Net Change

Pfizer's Xeljanz Combo Comparable to AbbVie's Humira

by Zacks Equity Research Published on February 17,2017

Pfizer, Inc. (PFE) announced top-line results from a head-to-head study comparing its rheumatoid arthritis (RA) drug Xeljanz with AbbVie, Inc.'s (ABBV) Humira.

• PFE Quick QuotePFEPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• AMGN Quick QuoteAMGNPositive Net Change
• ABBV Quick QuoteABBVPositive Net Change

Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

by Zacks Equity Research Published on February 15,2017

Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.

• PFE Quick QuotePFEPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change

Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

by Zacks Equity Research Published on February 13,2017

The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

• PFE Quick QuotePFEPositive Net Change
• LLY Quick QuoteLLYPositive Net Change
• JNJ Quick QuoteJNJPositive Net Change
• GILD Quick QuoteGILDPositive Net Change

4 Drug Stocks that are Broker Favorites

by Arpita Dutt Published on February 07,2017

Here's a look at 4 drug stocks preferred by analysts who have a deep knowledge and understanding of the industry and its companies.

• JNJ Quick QuoteJNJPositive Net Change
• CELG Quick QuoteCELGPositive Net Change
• ALIOF Quick QuoteALIOFNo Net Change
• EXEL Quick QuoteEXELPositive Net Change